|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,450.00 JPY | -4.73% |
|
-3.27% | +2.40% |
| 03-26 | Renascience Inc. cancelled the transaction announced on November 28, 2025 | CI |
| 03-05 | Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc. | CI |
| Market Cap | 20.97B 129M 113M 104M 95.74M 181M 12.44B 184M 1.24B 489M 6.07B 485M 474M | P/E 2025 |
118x | P/E 2026 | -71.8x |
|---|---|---|---|---|---|
| Enterprise Value | 17.57B 108M 94.52M 87.41M 80.21M 152M 10.42B 154M 1.04B 410M 5.09B 406M 397M | EV / Sales 2025 |
87.3x | EV / Sales 2026 | 290x |
| Free-Float |
47.66% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | -4.73% | ||
| 1 week | -3.27% | ||
| Current month | -6.93% | ||
| 1 month | -10.66% | ||
| 3 months | +0.28% | ||
| 6 months | -10.82% | ||
| Current year | +2.40% |
| 1 week | 1,411 |  | 1,771 |
| 1 month | 1,360 | | 1,771 |
| Current year | 1,108 | | 2,185 |
| 1 year | 1,108 | | 3,310 |
| 3 years | 263 | | 3,310 |
| 5 years | 263 | | 3,310 |
| 10 years | 263 | | 3,310 |
| Manager | Title | Age | Since |
|---|---|---|---|
Keisuke Furuta
PSD | President | 38 | 01/06/2024 |
Sho Kato
CTO | Chief Tech/Sci/R&D Officer | 38 | 01/06/2021 |
Kahoru Hori
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Toshio Miyata
CHM | Chairman | 65 | 01/04/2020 |
Sho Kato
BRD | Director/Board Member | 38 | 01/06/2021 |
Keisuke Furuta
BRD | Director/Board Member | 38 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.73% | -3.27% | -47.77% | +194.12% | 129M | |
| +1.08% | -3.93% | +48.03% | +160.13% | 1,043B | |
| +1.19% | -3.52% | +51.70% | +56.36% | 602B | |
| +4.21% | +1.79% | +33.48% | +87.04% | 449B | |
| -0.03% | -1.46% | +29.07% | +23.68% | 327B | |
| +0.75% | -0.26% | +32.80% | +45.97% | 279B | |
| -0.93% | -2.48% | +21.37% | +22.71% | 264B | |
| +3.70% | +2.19% | +24.27% | +63.38% | 201B | |
| +3.49% | +1.08% | +24.08% | +76.58% | 169B | |
| +1.29% | +3.67% | +2.15% | -30.78% | 143B | |
| Average | +0.73% | -0.14% | +21.92% | +69.92% | 347.72B | |
| Weighted average by Cap. | +1.50% | -1.82% | +37.33% | +82.78% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 132M 813K 710K 657K 603K 1.14M 78.3M 1.16M 7.83M 3.08M 38.23M 3.05M 2.98M | 68M 419K 366K 338K 310K 588K 40.33M 598K 4.04M 1.59M 19.7M 1.57M 1.54M |
| Net income | 113M 696K 608K 562K 516K 977K 67.03M 993K 6.71M 2.63M 32.73M 2.61M 2.55M | -301M -1.85M -1.62M -1.5M -1.37M -2.6M -179M -2.65M -17.86M -7.02M -87.18M -6.96M -6.81M |
| Net Debt | -1.8B -11.07M -9.68M -8.95M -8.21M -15.55M -1.07B -15.82M -107M -41.94M -521M -41.59M -40.67M | -3.4B -20.94M -18.3M -16.93M -15.53M -29.4M -2.02B -29.91M -202M -79.31M -985M -78.64M -76.91M |
Employees
3
Sector
Pharmaceuticals
Calendar
08-14 -
Earnings release - Q1 2027
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | ¥1,450.00 | -4.73% | 349,000 |
| 16/07/26 | ¥1,522.00 | -2.25% | 533,000 |
| 15/07/26 | ¥1,557.00 | -4.48% | 520,000 |
| 14/07/26 | ¥1,630.00 | +10.81% | 1,907,300 |
| 13/07/26 | ¥1,471.00 | -1.87% | 129,300 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4889 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
